80
Participants
Start Date
April 17, 2025
Primary Completion Date
March 31, 2029
Study Completion Date
June 30, 2029
Health Education
Health Education
Subspecialty clinic referral
This intervention will entail referred to establish clinical care in either the MGH Lipid and Metabolism Clinic or the MGH Renal Clinic for consideration of SGLT2 inhibitor therapy. SGLT2 inhibitor therapy (e.g. empagliflozin 10 mg by mouth daily or dapagliflozin 10 mg by mouth daily) may or may not be prescribed by the subspecialty clinician as part of routine clinical care, according to the clinician's clinical judgement.
RECRUITING
Massachusetts General Hospital, Boston
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Massachusetts General Hospital
OTHER